nodes	percent_of_prediction	percent_of_DWPC	metapath
Masoprocol—IGF1R—TSH signaling pathway—CGA—conduct disorder	0.104	0.142	CbGpPWpGaD
Masoprocol—Dobutamine—COMT—conduct disorder	0.0909	0.343	CrCbGaD
Masoprocol—CYP19A1—FSH signaling pathway—CGA—conduct disorder	0.0719	0.0979	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism of steroid hormones and vitamin D—CGA—conduct disorder	0.0613	0.0833	CbGpPWpGaD
Masoprocol—Dopamine—COMT—conduct disorder	0.0444	0.167	CrCbGaD
Masoprocol—L-DOPA—DRD4—conduct disorder	0.0387	0.146	CrCbGaD
Masoprocol—Dopamine—DRD4—conduct disorder	0.036	0.136	CrCbGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0353	0.0481	CbGpPWpGaD
Masoprocol—Dopamine—MAOA—conduct disorder	0.0335	0.126	CrCbGaD
Masoprocol—CYP2J2—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.03	0.0409	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—CGA—conduct disorder	0.0269	0.0366	CbGpPWpGaD
Masoprocol—LTB4R—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0231	0.0314	CbGpPWpGaD
Masoprocol—Dopamine—SLC6A4—conduct disorder	0.0216	0.0814	CrCbGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0198	0.0269	CbGpPWpGaD
Masoprocol—LTB4R—G alpha (q) signalling events—HTR2A—conduct disorder	0.0195	0.0265	CbGpPWpGaD
Masoprocol—LTB4R—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.0174	0.0237	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways in Glioblastoma—EP300—conduct disorder	0.017	0.0231	CbGpPWpGaD
Masoprocol—CYP2J2—Biological oxidations—COMT—conduct disorder	0.0161	0.0219	CbGpPWpGaD
Masoprocol—CYP2J2—Biological oxidations—MAOA—conduct disorder	0.016	0.0217	CbGpPWpGaD
Masoprocol—CYP2J2—Metapathway biotransformation—COMT—conduct disorder	0.0159	0.0216	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—CGA—conduct disorder	0.0152	0.0207	CbGpPWpGaD
Masoprocol—LTB4R—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0151	0.0205	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—DRD4—conduct disorder	0.0151	0.0205	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—CGA—conduct disorder	0.0138	0.0188	CbGpPWpGaD
Masoprocol—CYP19A1—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.0138	0.0188	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.0137	0.0186	CbGpPWpGaD
Masoprocol—LTB4R—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.0129	0.0176	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.0122	0.0166	CbGpPWpGaD
Masoprocol—LTB4R—GPCR ligand binding—HTR2A—conduct disorder	0.00983	0.0134	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—DRD4—conduct disorder	0.00852	0.0116	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—CGA—conduct disorder	0.00816	0.0111	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—DRD4—conduct disorder	0.00773	0.0105	CbGpPWpGaD
Masoprocol—CYP19A1—Biological oxidations—COMT—conduct disorder	0.00738	0.01	CbGpPWpGaD
Masoprocol—CYP19A1—Biological oxidations—MAOA—conduct disorder	0.00733	0.00997	CbGpPWpGaD
Masoprocol—CYP19A1—Metapathway biotransformation—COMT—conduct disorder	0.00728	0.0099	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—CGA—conduct disorder	0.00694	0.00944	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—WASF1—conduct disorder	0.00654	0.0089	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00628	0.00854	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—CGA—conduct disorder	0.00609	0.00829	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—WASF1—conduct disorder	0.00556	0.00757	CbGpPWpGaD
Masoprocol—LTB4R—GPCR downstream signaling—HTR2A—conduct disorder	0.00556	0.00756	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—CGA—conduct disorder	0.00543	0.00739	CbGpPWpGaD
Masoprocol—LTB4R—Signaling by GPCR—HTR2A—conduct disorder	0.00505	0.00687	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—DRD4—conduct disorder	0.00457	0.00622	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—DRD4—conduct disorder	0.00389	0.00529	CbGpPWpGaD
Masoprocol—CYP19A1—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.00351	0.00478	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—HTR2A—conduct disorder	0.00298	0.00406	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—CGA—conduct disorder	0.0028	0.0038	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—COMT—conduct disorder	0.00275	0.00374	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—MAOA—conduct disorder	0.00273	0.00371	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.00265	0.0036	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—HTR2A—conduct disorder	0.00253	0.00345	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—COMT—conduct disorder	0.00245	0.00333	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—MAOA—conduct disorder	0.00243	0.00331	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.00236	0.00321	CbGpPWpGaD
Masoprocol—LTB4R—Signaling Pathways—EP300—conduct disorder	0.00158	0.00215	CbGpPWpGaD
Masoprocol—IGF1R—Signaling Pathways—EP300—conduct disorder	0.00134	0.00183	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—COMT—conduct disorder	0.00126	0.00172	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—MAOA—conduct disorder	0.00125	0.00171	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.00122	0.00165	CbGpPWpGaD
Masoprocol—CYP2J2—Metabolism—EP300—conduct disorder	0.00118	0.0016	CbGpPWpGaD
Masoprocol—ALOX5—Metabolism—EP300—conduct disorder	0.00105	0.00143	CbGpPWpGaD
Masoprocol—CYP19A1—Metabolism—EP300—conduct disorder	0.000541	0.000736	CbGpPWpGaD
